Targeting G protein-coupled receptor signalling by blocking G proteins

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• G protein-coupled receptors (GPCRs) are a major drug target class due to their efficacy and diversity.
• Targeting individual GPCR subtypes may be insufficient for complex diseases involving multiple pathways.
• An alternative strategy involves targeting G protein subunits to modulate GPCR signaling.

Purpose of the Study:

• To review the development and characterization of ligands targeting G protein subunits (α and βγ).
• To discuss the therapeutic potential of G protein subunit-targeted drugs in various disease models.
• To highlight the advantages of targeting G protein subunits over GPCRs directly.

Main Methods:

• Review of preclinical studies and literature on G protein subunit ligands.
• Analysis of drug development strategies focusing on G protein α and βγ-subunits.
• Examination of biased signaling inhibition by G protein subunit modulators.

Main Results:

• Molecules targeting G protein α or βγ-subunits have demonstrated efficacy in preclinical disease models.
• These ligands can achieve biased inhibition of G protein signaling pathways.
• Development of specific ligands for G protein subunits is advancing.

Conclusions:

• Targeting G protein subunits presents a promising therapeutic approach for multifactorial diseases.
• This strategy offers potential for broad efficacy by modulating shared signaling pathways.
• Potential therapeutic applications include pain, thrombosis, asthma, and heart failure.